<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415818</url>
  </required_header>
  <id_info>
    <org_study_id>TG4010.09</org_study_id>
    <nct_id>NCT00415818</nct_id>
  </id_info>
  <brief_title>Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transgene</source>
  <brief_summary>
    <textblock>
      The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in
      comparison with chemotherapy alone in patients with advanced non small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the experimental arm patients receive subcutaneous injections of TG4010 at the dose of 108
      pfu in combination with chemotherapy treatment whereas patients in the control arm receive
      chemotherapy alone. The chemotherapy associates cisplatin and gemcitabine and is given for up
      to 6 cycles or progressive disease, whichever occurs first.

      TG4010 is administered once per week for 6 weeks, then once every 3 weeks in combination with
      chemotherapy and thereafter as monotherapy until documentation of progressive disease.

      Tumor response will be evaluated every 6 weeks by a CT-scan and results will be available
      before starting an additional treatment period of 6 weeks. The tumor response taken into
      account will be for each patient the best overall response obtained during the study.

      The endpoint of the study is based on Progression Free Survival (PFS) at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate according to WHO criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVA-MUC1-IL2 in combination with 1st line Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1st line Chemotherapy without a MVA-MUC1-IL2 combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-MUC1-IL2</intervention_name>
    <description>MVA-MUC1-IL2:
Dose of 10exp8 plaque forming units (pfu).
Chemotherapy:
Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1st line Chemotherapy</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-small cell carcinoma of the lung (adenocarcinoma,
             squamous cell carcinoma, or large cell carcinoma);

          -  Histological documentation of MUC1 antigen expression on the primary tumor or on
             metastasis, as defined by a positive staining by immuno-histo-chemistry in at least
             25% of the tumor cells in the conditions described in the technical documentation of
             the monoclonal antibody;

          -  Patients will have stage IIIb &quot;wet&quot; (with pleural or pericardial effusion) or IV
             disease, with no prior systemic therapy for advanced disease except for adjuvant
             treatment. Prior surgery or radiation therapy aimed at local palliation or attempted
             local disease control is permitted;

          -  At least one measurable lesion by Computed Tomography (CT-scanner) according to WHO
             criteria (lesion accurately measured in two dimensions with longest diameter equal or
             greater to 10 mm with spiral CT scan);

          -  Adequate hematological, hepatic, and renal function:

               -  Hemoglobin &gt;= 10.0 g/dL; WBC &gt;= 3.0x10e9/L including neutrophils &gt;= 1.5x10e9/L
                  and total lymphocytes count &gt;= 0.5x10e9/L; platelets count &gt;= 100x10e9/L;

               -  Bilirubin =&lt; 2x the upper limit of normal and serum transaminases =&lt; 3x the upper
                  limit of normal;

               -  Glomerular Filtration Rate higher than 60 ml/mn according to Cockcroft formula;

          -  Performance status 0 or 1 on the ECOG scale (Appendix 2);

          -  Minimum estimated life expectancy of 4 months;

          -  Written informed consent from patient.

        Exclusion Criteria:

          -  Concomitant brain metastases. If previous brain metastases were treated, the absence
             of evolution is to be demonstrated by the MRI or scanner performed at baseline;

          -  Prior history of other malignancy except basal cell carcinoma and intra-epithelial
             cervical cancer or other cancer with complete response since at least 5 years;

          -  History of any form of systemic therapy for advanced non-small cell cancer of the lung
             except for (neo)adjuvant treatment;

          -  Previous (within 4 weeks prior to day 1) or concomitant long term treatment with
             systemic steroids, immunosuppressive / immunomodulating drugs (e.g. Cyclosporine,
             corticoïds);

          -  Positive serology for HIV or HCV; positive antigens for hepatitis B;

          -  Serious concomitant medical disorder;

          -  Major surgery within 4 weeks prior to day 1;

          -  Patient with an organ allograft;

          -  Allergy to eggs;

          -  Participation in another experimental protocol during the study period, or within 4
             weeks prior to day 1;

          -  Pregnancy at the entry or women who are breast feeding;

          -  Patient without adequate protection against pregnancy during the conduct of the study
             and for 3 months after the last injection of TG4010 and/or chemotherapy;

          -  History of substance abuse;

          -  Patient unable or unwilling to comply with the protocol requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth QUOIX, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Lyautey, Service de Pneumologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Belfort-Montbeliard</name>
      <address>
        <city>Belfort</city>
        <zip>90016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU, Service de Pneumologie</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général, Service de Pneumologie</name>
      <address>
        <city>Briey</city>
        <zip>54151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur - Service de médecine F- Pavillon 43</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes, Service d'oncologie médicale</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lyautey - Service de Pneumologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Haute Saône, Service de Pneumologie - Allergologie</name>
      <address>
        <city>Vesoul</city>
        <zip>70014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken, Zentrum für Pneumonologie</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Krankenhaus Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim der Ruprecht-Karls</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Offenburg, Medizinische Klinik II</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejér Megyei Szent György Kórház</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział II Chorób Płuc i Gruźlicy</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kujawsko-Pomorskie Centrum Pulmonologii</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-326</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Chemioterapii</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział III Chorób Płuc i Gruźlicy</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Onkologii Klinicznej</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnośląskie Centrum</name>
      <address>
        <city>Wrocław</city>
        <zip>53-439</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/lungcancer.html</url>
  </link>
  <results_reference>
    <citation>Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011 Nov;12(12):1125-33. doi: 10.1016/S1470-2045(11)70259-5. Epub 2011 Oct 21.</citation>
    <PMID>22019520</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Cancer Vaccine</keyword>
  <keyword>Stage IV Non-Small Cell Lung Cancer</keyword>
  <keyword>Stage IIIb Non-Small Cell Lung Cancer with effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

